Pyxis Oncology (NASDAQ:PYXS) Lowered to Sell Rating by Wall Street Zen

Pyxis Oncology (NASDAQ:PYXS) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Sunday.

Several other equities analysts have also recently commented on the stock. Stephens boosted their target price on shares of Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. Royal Bank Of Canada reduced their price target on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research report on Thursday, December 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday, January 22nd. Finally, HC Wainwright boosted their price objective on shares of Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $7.20.

Pyxis Oncology Stock Up 0.7%

PYXS opened at $1.54 on Friday. The stock has a market capitalization of $95.88 million, a price-to-earnings ratio of -0.96 and a beta of 1.45. Pyxis Oncology has a twelve month low of $0.83 and a twelve month high of $5.55. The company has a 50-day simple moving average of $1.53 and a 200 day simple moving average of $2.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in PYXS. Maia Wealth LLC acquired a new stake in shares of Pyxis Oncology in the 4th quarter valued at approximately $25,000. Engineers Gate Manager LP acquired a new position in Pyxis Oncology during the 4th quarter worth approximately $26,000. Fox Run Management L.L.C. bought a new position in Pyxis Oncology in the 4th quarter valued at approximately $26,000. Catalyst Funds Management Pty Ltd acquired a new stake in Pyxis Oncology in the second quarter valued at approximately $26,000. Finally, Avanza Fonder AB acquired a new stake in Pyxis Oncology in the fourth quarter valued at approximately $31,000. Institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.